Skip to content

US · CALC · BIOTECHNOLOGY

CalciMedica, Inc. (CALC) intrinsic value and stock valuation

$1.26as of 2026-11-21 · Mkt cap 10.82M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

CalciMedica, Inc. DCF and intrinsic value

InvestorsCraft values CALC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CALC’s statements →

CalciMedica, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology La Jolla, CA 92037 calcimedica.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-29.56M
20182025
Free cash flow
-$-21.21M
20182025
Total equity
-$-6.64M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-23.12M-$-24.2M-$-38.08M-$-14.19M-$-35.95M
Net income-$-29.56M-$-13.7M-$-34.36M-$-7.82M-$-35.82M
EPSd-$-1.97K-$-1.22M-$-7.65M-$-5.11M-$-23.72M
Operating cash flow-$-21.18M-$-21.15M-$-25.73M-$-11.76M-$-31.5M
Capital expenditure-$-30K-$-10K-$-80K-$0.00-$-490K
Free cash flow-$-21.21M-$-21.15M-$-25.81M-$-11.76M-$-31.99M
Total assets$13.6M$19.8M$12.2M$3.35M$69.1M
Total debt$9.7M$0.00$0.00$5.36M$0.00
Net debt-$-1.82M-$-7.93M-$-5.53M$4.03M-$-13.36M
Total equity-$-6.64M$14.4M$8.16M-$-9.23M$65M
Cash and short-term investments$13M$18.7M$11.2M$1.33M$63.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$50K$0.00$0.00$0.00$520K
Gross profit-$-50K$0.00$0.00$0.00-$-520K
Research and development expenses$15.2M$14.5M$15.9M$8.35M$18.9M
Selling, general and administrative expenses$7.89M$9.73M$22.2M$5.84M$17M
Other expenses$0.00$0.00$0.00$0.00-$-520K
Operating expenses$23.1M$24.2M$38.1M$14.2M$35.4M
Cost and expenses$23.1M$24.2M$38.1M$14.2M$36M
Interest income$710K$0.00$0.00$0.00$130K
Interest expense$1.42M$0.00$110K$130K$130K
Depreciation and amortization$50K$60K$60K$50K$520K
Ebitda-$-28.09M-$-13.64M-$-34.19M-$-7.64M-$-35.3M
Operating income-$-23.12M-$-24.2M-$-38.08M-$-14.19M-$-35.95M
Total other income/expenses, net-$-6.44M$10.5M$3.72M$6.37M$130K
Income before tax-$-29.56M-$-13.7M-$-34.36M-$-7.82M-$-35.82M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-29.56M-$-13.7M-$-34.36M-$-7.82M-$-35.82M
Weighted average shares outstanding$15B$11.3M$4.49M$1.53M$1.51M
Weighted average diluted shares outstanding$15B$11.3M$4.49M$1.53M$1.51M
Balance sheet
20252024202320222021
Cash and short-term investments$13M$18.7M$11.2M$1.33M$63.7M
Net receivables$0.00$0.00$0.00$40K$20K
Inventory$0.00$0.00$0.00$0.00-$-20K
Total current assets$13.5M$19.7M$11.6M$1.73M$67.1M
Property, plant and equipment, net$50K$120K$170K$200K$1.98M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$60K$130K$580K$1.62M$2.01M
Total assets$13.6M$19.8M$12.2M$3.35M$69.1M
Accounts payable$1.16M$2M$1.42M$2.87M$530K
Short-term debt$1.25M$0.00$0.00$200K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$10K
Total current liabilities$3.78M$3.68M$4.03M$4.78M$4.06M
Long-term debt$8.45M$0.00$0.00$5.16M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$10K
Total non-current liabilities$16.5M$1.7M$0.00$7.8M$10K
Capital lease obligations$0.00$0.00$0.00$200K$0.00
Total liabilities$20.2M$5.38M$4.03M$12.6M$4.07M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-189.33M-$-159.76M-$-146.06M-$-111.71M-$-169.19M
Accumulated other comprehensive income (loss)-$0.00$0.00$0.00-$-40K-$-20K
Total equity-$-6.64M$14.4M$8.16M-$-9.23M$65M
Total investments$1.5M$10.7M$5.71M$0.00$50.3M
Total debt$9.7M$0.00$0.00$5.36M$0.00
Net debt-$-1.82M-$-7.93M-$-5.53M$4.03M-$-13.36M
Cash flow statement
20252024202320222021
Net income-$-29.56M-$-13.7M-$-34.36M-$-7.82M-$-35.82M
Depreciation and amortization$50K$60K$60K$50K$520K
Stock-based compensation$2.97M$2.31M$12M$1.81M$5.38M
Change in working capital-$-620K-$-490K-$-270K$600K-$-1.63M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-840K$600K-$-1.43M$930K-$-2.05M
Net cash provided by operating activities-$-21.18M-$-21.15M-$-25.73M-$-11.76M-$-31.5M
Investments in property, plant and equipment-$-30K-$-10K-$-80K-$0.00-$-490K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$9.55M-$-4.42M$8.88M-$0.00$10.8M
Common stock issued$5.55M$28M$25.5M$20K$690K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$15.2M$28M$20.9M$8.48M$690K
Net change in cash$3.58M$2.4M$4.05M-$-3.29M-$-20.05M
Cash at end of period$11.5M$7.93M$5.53M$1.48M$13.4M
Operating cash flow-$-21.18M-$-21.15M-$-25.73M-$-11.76M-$-31.5M
Capital expenditure-$-30K-$-10K-$-80K-$0.00-$-490K
Free cash flow-$-21.21M-$-21.15M-$-25.81M-$-11.76M-$-31.99M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About CalciMedica, Inc.

        CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.

        CEO
        A. Rachel Leheny
        Employees
        16
        Beta
        1.11

        Explore

        Frequently asked questions

        What is the intrinsic value of CalciMedica, Inc. (CALC)?

        InvestorsCraft does not currently publish an intrinsic value for CALC. How the IC value is calculated.

        Is CALC undervalued?

        InvestorsCraft does not publish an undervaluation signal for CALC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.